Global menu

Our global pages

Mark Crane, Senior Associate

Mark Crane

Senior Associate

Practice areas

  • Competition, EU and Trade
  • Energy and infrastructure
  • Health and life sciences
  • Inquiries and investigations
  • Retail

Practice notes

Mark is a senior associate in our Competition, EU and Trade group.

He advises on a variety of EU and UK competition law issues including merger control, behavioural investigations, market investigations and the application of competition law to commercial agreements and arrangements. Mark also assists clients in developing their competition compliance programmes. He has worked with clients from a range of sectors including healthcare, financial services, transport, fast-moving consumer goods and private equity. Mark also advises clients in regulated sectors, particularly the water sector. Prior to joining Eversheds Sutherland, Mark worked in London and Brussels for a leading international law firm.

Mark's recent experience includes:

  • Assisting a client on an unannounced inspection ('dawn raid') by the Competition and Markets Authority and advising on the subsequent investigation;
  • Advising two water companies on the EU and UK merger control aspects (gaining unconditional clearance) of a recent non-household retail water joint venture;
  • Advising a client on the UK merger control aspects (gaining unconditional clearance) of its acquisition of a competitor;
  • Advising clients in the water and energy sectors on competition law issues involved in both strategic collaborations and day to day commercial arrangements;
  • Designing, implementing and advising on competition law compliance programmes for a number of clients across various sectors;
  • Advising SABMiller plc on the merger control aspects of AB InBev's acquisition of SABMiller as well as advising on competition law compliance in integration and divestment planning;
  • Advising Novartis on the merger control aspects (including remedies) of the acquisition of GSK's oncology business and the merger control aspects of the divestment of its flu business to CSL. Mark was part of the team which was awarded with the Financial Times's award for Innovative Lawyers in the categories "Competition" and "Outstanding innovation of 2015" for their work on the remedy Novartis had to offer in order to obtain approval for purchasing GSK's oncology business;
  • A secondment to the in-house competition law team at a major global pharmaceutical company, advising on both strategic and day-to-day competition law issues.
Winners of the Global Competition Review award for behavioural matter of the year (Europe). This was for the creative, strategic and innovative work carried out in a non-merger matter before an enforcer in Europe.